Tvardi Therapeutics (TVRD) Income from Continuing Operations (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Income from Continuing Operations of 7552000.0 for Q1 2026, up 13.12% sequentially from 8692000.0 in Q4 2025, and up 21.16% YoY from 6233035.33 in Q1 2025.
Tvardi Therapeutics (TVRD) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Income from Continuing Operations for 14 years, with the latest figure at 7552000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 21.16% year-over-year to 7552000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 82164000.0 (down 120.46% YoY) and the FY2025 annual result came in at 27826000.0, up 60.73% from the prior year.
- Income from Continuing Operations advanced to 7552000.0 in Q1 2026 per TVRD's latest filing, from 8692000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 7096000.0 in Q2 2024 and troughed at 39999000.0 in Q3 2025.
- A 5-year average of 21929941.18 and a median of 26331000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations slumped 2499.31% in 2022, then soared 78.39% in 2024.
- Over 5 years, Income from Continuing Operations stood at 31801000.0 in 2022, then decreased by 4.12% to 33110000.0 in 2023, then soared by 67.63% to 10719000.0 in 2024, then increased by 18.91% to 8692000.0 in 2025, then climbed by 13.12% to 7552000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 7552000.0, 8692000.0, and 39999000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | -6.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.55 Mn |
| Dec 31, 2025 | -8.69 Mn |
| Sep 30, 2025 | -40.00 Mn |
| Jun 30, 2025 | -25.92 Mn |
| Mar 31, 2025 | -9.58 Mn |
| Dec 31, 2024 | -10.72 Mn |
| Sep 30, 2024 | -9.88 Mn |
| Jun 30, 2024 | -7.10 Mn |
| Mar 31, 2024 | -31.03 Mn |
| Dec 31, 2023 | -33.11 Mn |
| Sep 30, 2023 | -30.30 Mn |
| Jun 30, 2023 | -32.84 Mn |
| Mar 31, 2023 | -29.15 Mn |
| Dec 31, 2022 | -31.80 Mn |
| Sep 30, 2022 | -26.33 Mn |
| Jun 30, 2022 | -7.45 Mn |
| Mar 31, 2022 | -31.38 Mn |
| Dec 31, 2021 | -33.38 Mn |
| Sep 30, 2021 | -1.01 Mn |
| Jun 30, 2021 | -30.75 Mn |